Crenolanib is primarily used in cancer research and therapy, specifically targeting tumors driven by mutations in the PDGFRA and PDGFRB genes. It shows strong inhibitory activity against the platelet-derived growth factor receptor (PDGFR) family, particularly the alpha and beta isoforms, which are often implicated in certain leukemias and gastrointestinal stromal tumors (GISTs). It has gained attention for its effectiveness in treating cancers resistant to other tyrosine kinase inhibitors, especially in patients with FIP1L1-PDGFRA fusion-positive chronic eosinophilic leukemia. Crenolanib is also being investigated in clinical trials for its potential in managing glioblastoma and other solid tumors where PDGFR signaling plays a key role in tumor growth and angiogenesis. Due to its selective mechanism, it helps block tumor cell proliferation, survival, and metastasis by disrupting abnormal signaling pathways. Its application is mainly in targeted therapy, aiming to provide a more precise and less toxic alternative to conventional chemotherapy.